Bruker
BRKR
$57.59
+0.49%
Bruker Corporation designs and manufactures high-performance scientific instruments and analytical/diagnostic solutions for life-science research, pharma and biotech, applied and industrial markets, and semiconductor metrology, organized across BSI BioSpin (magnetic resonance), BSI CALID (mass spectrometry, microbiology and diagnostics, the largest revenue segment), BSI Nano (semiconductor and materials metrology), and Bruker Energy & Supercon Technologies (BEST). Bruker is a differentiated, high-end technology platform rather than a commodity device maker, competing with Thermo Fisher, Agilent, and Danaher on instrument performance and workflow depth while carrying a premium brand in academic and industrial research labs. The current investor debate centers on a sharp profitability reset: after a Q3 2025 loss and a Q2 2026 net loss of $52 million (EPS -$0.41) driven by elevated other expenses and a weak 2.1% EBITDA margin, the stock sold off violently on the August 4, 2026 print before recovering, and bulls now argue the trough is in as gross margin recovered to 49.6% and revenue grew 5.2% year over year. Sentiment is further shaped by the company's semiconductor metrology exposure (BSI Nano) and its role as a beneficiary of AI-driven lab automation and advanced-node inspection demand, offset by tariff, NIH/academic funding, and China exposure concerns that keep several sell-side analysts on the sidelines.…
BRKR
Bruker
$57.59
Investment Opinion: Should I buy BRKR Today?
Rating: Hold. The core thesis is that Bruker is a high-quality franchise with a temporarily depressed earnings profile, but the recovery is not yet confirmed. The analyst consensus is 'buy' with an average target of $63.83 (16.5% upside), yet the recent Neutral reiterations from UBS and Citigroup and the wide target range of $50-$80 reflect genuine disagreement about the margin trajectory. We recommend holding existing positions and waiting for clearer evidence of sustainable margin recovery before adding.
Supporting evidence: The PS ratio of 2.08x is at the low end of its historical range (5.7x-18.7x), suggesting the market has priced in much of the bad news. Gross margin recovered to 49.61% in Q2 2026 from 44.88% a year earlier, showing underlying product profitability. Revenue grew 5.15% year over year to $838.5 million, and the forward PE of 22.8x implies consensus EPS of $3.50, a significant rebound from the current loss. However, TTM FCF of $93.9 million is weak, and the PEG ratio of 2.62 indicates the stock is not cheap on growth-adjusted basis.
Risks and conditions: The biggest risks are a continued margin compression, negative free cash flow, and premium valuation on depressed earnings. This Hold would upgrade to Buy if operating margins recover above 10% and FCF turns sustainably positive, or if the stock pulls back to the $50 analyst low target (9% downside). It would downgrade to Sell if revenue growth decelerates below 3% or if operating margins fail to improve by the next earnings report. Valuation verdict: fairly valued to slightly overvalued on current earnings, but undervalued if the recovery materializes.
Sign up to view all
BRKR 12-Month Price Forecast
Bruker is a high-quality franchise undergoing a painful earnings reset, with the stock down 9.68% in the past month despite a 43.46% one-year gain. The gross margin recovery to 49.61% is encouraging, but the operating loss and negative free cash flow show the recovery is not yet complete. Valuation is mixed: the PS ratio of 2.08x is historically low, but the forward PE of 22.8x and EV/EBITDA of 29.4x are premium multiples that require margin normalization. We would upgrade to bullish if operating margins recover above 10% and FCF turns positive, and downgrade to bearish if revenue growth decelerates below 3% or margins fail to improve by the next earnings report.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bruker's 12-month outlook, with a consensus price target around $63.83 and implied upside of +10.8% versus the current price.
Average Target
$63.83
0 analysts
Implied Upside
+10.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$50 - $80
Analyst target range
Twelve analysts cover Bruker with a consensus recommendation of "buy" (mean rating 2.31 on a scale where lower is more bullish), and the average target price of $63.83 implies roughly +16.5% upside from the current $54.80. The distribution skews constructive, with recent actions including Leerink Partners reiterating Outperform (September 29, 2026), Guggenheim at Buy, Barclays and JP Morgan at Overweight, while UBS and Citigroup remain Neutral, indicating the bullish case is held by a majority but not overwhelmingly. Consensus estimates of $3.50 EPS and $4.44 billion revenue for the forward period underpin the target and imply the Street expects a meaningful earnings rebound from the current loss-making quarter.
The target range of $50.00 to $80.00 is wide, spanning about 60% from low to high, which signals genuine disagreement about the margin trajectory rather than mere noise. The $80 high target likely assumes operating margins recover toward the high-teens, semiconductor metrology demand accelerates, and the forward PE re-rates toward the mid-20s; the $50 low target effectively prices in continued margin compression, weak academic/China demand, and a stalled earnings recovery, sitting only about 9% below the current price. Notably, no analyst has downgraded in the recent ratings history, but the repeated Neutral reiterations from UBS and Citigroup suggest conviction is concentrated in a bull camp that needs the next earnings print to validate the recovery thesis; with a 5.52 short ratio and beta of 1.223, the stock remains prone to sharp moves around catalysts.
Drowning in data?
Find the real signal!
Bulls vs Bears: BRKR Investment Factors
The bull case rests on a gross margin recovery to 49.61%, a consensus buy rating with 16.5% upside to the average target, and a historically low PS multiple of 2.08x that could re-rate if margins normalize. However, the bear case is currently stronger: the company reported a net loss of $52 million in Q2 2026, operating margin is -7.79%, and free cash flow turned negative at -$106.2 million due to a $196.9 million working-capital drain. Revenue growth of 5.15% is below historical trends, and the forward PE of 22.8x is a premium to peers despite depressed earnings. The most important tension is whether the margin recovery is sustainable—if operating margins return to high-teens, the stock is undervalued; if the margin reset is structural, the stock is fairly to richly valued on EBITDA.
Bullish
- Gross margin recovery signals trough: Q2 2026 gross margin rebounded to 49.61% from 44.88% a year earlier, despite revenue growing only 5.15%. This 473-basis-point improvement shows pricing power and cost control at the product level, and if sustained, could drive significant operating leverage as other expenses normalize.
- Analyst consensus buy with 16.5% upside: Twelve analysts rate BRKR a 'buy' (mean 2.31) with an average target of $63.83, implying 16.5% upside from $54.80. Recent reiterations from Leerink (Outperform), Guggenheim (Buy), Barclays and JP Morgan (Overweight) suggest conviction in the recovery story.
- Attractive price-to-sales versus history: The current PS ratio of 2.08x sits at the very bottom of its historical 5.7x-18.7x range, reflecting the earnings collapse rather than multiple expansion. If margins normalize, this valuation provides a margin of safety and potential for multiple re-rating.
- Semiconductor metrology upside: BSI Nano segment exposure to advanced-node inspection and AI-driven lab automation positions Bruker to benefit from secular growth in semiconductor capital spending. This segment could accelerate revenue growth beyond the current 5.15% pace.
Bearish
- Profitability collapse with negative margins: Q2 2026 net income was -$52 million (-6.20% net margin) and operating margin -7.79%, driven by $148.1 million in other expenses. TTM operating margin is only 6.87% and net margin -0.25%, showing the company is barely profitable on a trailing basis.
- Cash flow deterioration and working capital drain: Q2 2026 operating cash flow was -$77.4 million and free cash flow -$106.2 million, driven by a $196.9 million working-capital drain. TTM FCF is only $93.9 million, and the erratic quarterly pattern raises concerns about cash generation sustainability.
- Premium valuation on depressed earnings: The forward PE of 22.8x and EV/EBITDA of 29.4x are premium multiples relative to medical-device peers in the high-teens to low-20s. The PEG ratio of 2.62 suggests investors are paying up for a recovery that has yet to materialize in reported results.
- Revenue growth decelerating below historical trend: Q2 2026 revenue grew only 5.15% year over year, below Bruker's historical high-single-digit trajectory. The sequential step-down from Q4 2025 to Q1 2026 was steeper than the prior year, indicating potential demand softness.
BRKR Technical Analysis
Bruker is in a choppy but net-positive recovery uptrend: the stock is up 43.46% over the past year versus a 15.53% gain for SPY, a 27.93-point relative-strength advantage, yet it sits only about 61% of the way through its 52-week range of $32.37 to $66.98, with the current $54.80 price roughly 18% below the high and 69% above the low. That mid-to-upper range positioning signals a stock that has repaired much of its 2025 damage but has not yet reclaimed momentum leadership, and the -39.85% max drawdown underscores how violent the prior de-rating was. The 6-month change of +34.64% confirms the recovery leg is real, but the failure to hold the $64-65 area in late September and early October leaves the trend technically unresolved.
Short-term momentum has clearly decelerated and now diverges from the longer-term uptrend: the stock is down 9.68% over the past month and 5.89% over three months, versus SPY gains of 1.22% and 2.69%, producing relative-strength readings of -10.90 (1-month) and -8.58 (3-month). The most recent session alone fell 3.08% on 1.67 million shares, and the sequence of lower highs from $64.75 on September 30 to $54.80 on October 16 suggests distribution rather than accumulation. This 1-month weakness against a +43% 1-year trend is best read as a mean-reversion pullback within a recovery, but if the decline extends through the October lows it would begin to look like a trend reversal rather than a pause.
Key technical levels are well defined: resistance sits at the $64.75-66.98 zone (the September 30 close and the 52-week high), and a decisive breakout above $67 would confirm the recovery and likely trigger momentum buying toward new highs, while support rests at the $52.66 September low and, more importantly, the $32.37 52-week low. A breakdown below $52.66 would put the August 4 gap area near $50.30 in play and signal that the post-earnings recovery has failed. With a beta of 1.223, Bruker is roughly 22% more volatile than the market, meaning position sizing should account for amplified drawdowns; the 5.52 short ratio also implies short sellers are not aggressively pressing the name, which modestly reduces squeeze-driven upside but also limits panic-selling risk.
Beta
1.22
1.22x market volatility
Max Drawdown
-39.9%
Largest decline past year
52-Week Range
$32-$67
Price range past year
Annual Return
+45.0%
Cumulative gain past year
| Period | BRKR Return | S&P 500 |
|---|---|---|
| 1m | -3.5% | -1.0% |
| 3m | -4.7% | +2.9% |
| 6m | +57.6% | +6.5% |
| 1y | +45.0% | +13.1% |
| ytd | +19.7% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BRKR Fundamental Analysis
Revenue is growing but at a modest, decelerating pace: Q2 2026 revenue of $838.5 million rose 5.15% year over year from $797.4 million, continuing a sequential climb from $823.4 million in Q1 2026 and $977.2 million in Q4 2025, though the Q4-to-Q1 seasonal step-down was steeper than the prior year's $979.6 million to $801.4 million pattern. Product revenue of $663.7 million plus $174.8 million of product-and-service other revenue shows the instrument franchise remains the core engine, with BSI CALID the largest segment per company disclosure. The 5% growth rate is below Bruker's historical high-single-digit trajectory and implies the investment case now hinges on margin recovery and semiconductor metrology upside rather than top-line acceleration.
Profitability has deteriorated sharply and is the central fundamental issue: Q2 2026 net income was -$52.0 million (net margin -6.20%, EPS -$0.41) versus +$7.6 million a year earlier, with operating income of -$65.3 million (-7.79% operating margin) and EBITDA of just $17.3 million (2.06% EBITDA margin) despite a healthy 49.61% gross margin that actually improved from 44.88% a year ago. The damage came below the gross line, with $148.1 million of other expenses and a $14.2 million tax charge on a pre-tax loss; trailing operating margin of 6.87% and net margin of -0.25% confirm the company is barely profitable on a TTM basis. Gross margin in the 46-50% band is respectable for analytical instruments, but the collapse in operating leverage means the market will demand evidence of cost discipline before re-rating the shares.
Balance-sheet and cash-flow quality are mixed: debt-to-equity is 0.83, the current ratio is 1.73, and TTM free cash flow is only $93.9 million, but the quarterly pattern is erratic, with Q2 2026 operating cash flow of -$77.4 million and FCF of -$106.2 million driven by a $196.9 million working-capital drain, following +$47.0 million FCF in Q1 2026 and +$207.2 million in Q4 2025. ROE of -0.35% and ROA of 3.14% are weak, and the $53.3 price-to-cash-flow ratio reflects depressed cash generation rather than a rich multiple. With $189.1 million of cash at quarter-end and ongoing debt repayment ($167.7 million in Q2), Bruker retains financing flexibility, but internal cash generation is not yet sufficient to comfortably fund growth and dividends without periodic balance-sheet reliance.
Quarterly Revenue
$838500000.0B
2026-06
Revenue YoY Growth
+5.1%
YoY Comparison
Gross Margin
49.6%
Latest Quarter
Free Cash Flow
$93900000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BRKR Overvalued?
Because trailing net income is negative (EPS of -$0.0012 and a trailing PE of -314.1x), the PE ratio is not meaningful and I am leading with the price-to-sales ratio of 2.08x and EV/sales of 2.95x, cross-checked against the forward PE of 22.80x. The gap between the unusable trailing PE and a 22.8x forward multiple implies the market expects a substantial earnings recovery, consistent with consensus EPS of $3.50 on $4.44 billion of revenue; the PEG ratio of 2.62 and EV/EBITDA of 29.4x show that on current depressed EBITDA the stock is not cheap, so the forward multiple is doing most of the valuation work.
Against the medical-devices sector, Bruker's 2.08x sales multiple and 2.91x price-to-book look modest, but its 29.4x EV/EBITDA and 22.8x forward PE are premium multiples relative to a sector where large-cap device peers typically trade in the high-teens to low-20s on forward earnings. The premium is defensible only if margins normalize toward the company's historical high-teens operating levels; on the current 6.87% operating margin and -0.25% net margin, the stock is expensive relative to its own profitability, and the 2.62 PEG ratio suggests investors are paying up for a recovery that has yet to appear in reported results.
Historically, Bruker's price-to-sales ratio has ranged from roughly 5.7x to 18.7x over the past several years, so the current 2.08x sits at the very bottom of its own band, while price-to-book of 2.91x compares with a historical range of roughly 2.0x to 11.9x. That compression reflects the earnings collapse rather than multiple expansion, and the forward PE of 22.8x versus historical trailing PEs that swung from 13x to over 300x shows how unreliable trailing earnings have become. The read-through is that the market is pricing a normalization scenario: if margins recover, today's sales multiple is cheap; if the margin reset proves structural, the stock is fairly to richly valued on EBITDA.
PE
-314.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~206x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated: Bruker reported a Q2 2026 net loss of $52 million (EPS -$0.41) and negative operating income of $65.3 million, driven by $148.1 million in other expenses. Free cash flow turned negative at -$106.2 million due to a $196.9 million working-capital drain, and TTM FCF is only $93.9 million. With debt-to-equity of 0.83 and a current ratio of 1.73, the balance sheet is not stretched, but the company's ability to fund growth and dividends without periodic balance-sheet reliance is a concern. Revenue concentration in BSI CALID (largest segment) and exposure to academic/China markets add operational risk.
Market and competitive risks include valuation compression: the forward PE of 22.8x and EV/EBITDA of 29.4x are premium multiples relative to medical-device peers, and the PEG ratio of 2.62 suggests the market is pricing a recovery that may not materialize. The beta of 1.223 means the stock is 22% more volatile than the market, amplifying drawdowns. Competitive threats from Thermo Fisher, Agilent, and Danaher in analytical instruments, plus regulatory headwinds from NIH/academic funding and tariffs, could pressure growth. Recent technical weakness (down 9.68% in the past month) and distribution patterns suggest waning momentum.
Worst-case scenario: A continued margin compression, weak academic/China demand, and a stalled earnings recovery could drive the stock toward the analyst low target of $50 (9% downside) or the 52-week low of $32.37 (41% downside). The max drawdown of -39.85% over the past year illustrates the potential severity. If the August 4 gap area near $50.30 is breached, the next support is the 52-week low, implying a loss of up to 41% from the current price of $54.80.
FAQ
The key risks are: 1) Financial risk: Q2 2026 net loss of $52 million and negative free cash flow of -$106.2 million, with TTM FCF only $93.9 million. 2) Valuation risk: forward PE of 22.8x and EV/EBITDA of 29.4x are premium multiples on depressed earnings, with PEG of 2.62. 3) Competitive/macro risk: exposure to academic/China funding and tariffs, plus competition from Thermo Fisher, Agilent, and Danaher. 4) Company-specific risk: revenue growth decelerated to 5.15%, below historical trends, and the stock is down 9.68% in the past month. The most severe risk is a continued margin compression leading to a break below $52.66 support, with downside to $32.37.
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $70-$80, assuming operating margins recover to high-teens and semiconductor metrology accelerates. Base case (50% probability) targets $60-$68, assuming mid-single-digit revenue growth and gradual margin improvement to 8-10%. Bear case (25% probability) targets $32-$50, assuming margin compression persists and revenue growth falls below 3%. The base case is most likely, with the key assumption that operating margins improve to 8-10% and forward EPS meets consensus of $3.50. The analyst average target of $63.83 aligns with our base case.
BRKR's valuation is mixed. The PS ratio of 2.08x is at the very bottom of its historical range (5.7x-18.7x), suggesting undervaluation on a sales basis. However, the forward PE of 22.8x and EV/EBITDA of 29.4x are premium multiples relative to medical-device peers, and the PEG ratio of 2.62 indicates the stock is not cheap on growth-adjusted earnings. The market is pricing a recovery: if margins normalize to high-teens, the stock is undervalued; if the margin reset is structural, it is fairly to richly valued. On balance, the stock appears fairly valued to slightly overvalued on current earnings, but undervalued if the recovery materializes.
From a risk/reward perspective, BRKR offers 16.5% upside to the analyst average target of $63.83, but the downside risk to the 52-week low of $32.37 is 41%. The stock is not cheap on current earnings (forward PE 22.8x, PEG 2.62), but the PS ratio of 2.08x is historically low. The biggest downside risk is a continued margin compression and negative free cash flow. It could be a good buy for long-term investors who believe in the margin recovery story, but only after the next earnings report confirms improving profitability. For risk-averse investors, waiting for a pullback to the $50 analyst low target or clearer evidence of recovery is prudent.
BRKR is more suitable for long-term investment (minimum 2-3 years) given its turnaround nature and high volatility (beta 1.223). The company is in a growth stage with a premium brand, but earnings visibility is low due to margin uncertainty. The dividend yield is negligible at 0.32%, so income is not a reason to hold. Short-term trading is risky due to the wide target range ($50-$80) and recent distribution patterns. A suggested minimum holding period is 18-24 months to allow for margin recovery and potential re-rating. Investors should monitor quarterly earnings for signs of sustainable improvement before committing capital.